The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Mechanisms of malignant progression
Open accessAbstract
While a coherent picture has begun to emerge about the biological and molecular mechanisms that create primary tumors, the processes that lead subsequently to invasion and metastasis have, until recently, been relatively obscure. However, over the past 5 years, research of diverse sorts has begun to generate the conceptual outlines that explain how high-grade malignancies arise. These discussions invariably are motivated by a widely accepted depiction of how metastatic dissemination occurs—the sequence termed the ‘invasion–metastasis cascade’ ( 1 ). Thus, primary tumor cells invade locally, enter into the circulation (intravasation), are transported through the circulation, are lodged in microvessels in distant tissues, invade the parenchyma of such tissue (extravasation) and form micrometastatic deposits, some of which eventually grow into macroscopic metastases, the last process being termed colonization. A major issue concerns the timing of acquisition of the ability to invade and metastasize. Is this ability a function of the great majority of cells within a primary tumor, or does it reflect the biology of a small subpopulation of cells in this tumor that have acquired the ability to invade and metastasize? If the great majority of cells in a primary tumor have a comparable if not identical ability to invade and metastasize, this suggests that such acquisition occurs early. Conversely, if these powers are an attribute of a relatively small subpopulation, this trait must be acquired relatively late during the course of primary tumor formation. This issue might be addressed by arguing from first principles. For example, if a subpopulation of cells that are especially favored to metastasize exists within a primary tumor, the clonal expansion of these cells would seem to have been favored during the successive mutation and selection cycles generating the clonal successions that drive multistep tumor pathogenesis forward. This model, however, confronts a conceptual difficulty: why should the phenotype of metastasis be selectively advantageous within the confines of a primary tumor? If it is not, this suggests that, to the extent that metastasis occurs, it does not represent a phenotype that has been actively selected during primary tumor formation ( 2 ). Accordingly, this phenotype may be an inadvertent consequence of the acquisition of alleles that did indeed confer growth advantage within the evolving primary tumor mass, that is, these alleles may act pleiotropically, encoding both selected phenotypes (growth and survival in the primary tumor) and unselected phenotypes (invasiveness and metastatic powers). Still, these arguments from first principles must give ground to empirical observations, since only the latter can definitively settle the early versus late debate. Here, one confronts the complexity of the invasion–metastasis cascade, which rivals that of the prior steps that led initially to the formation of a primary tumor. Accordingly, one can pose the question of whether the acquisition of metastatic traits requires the accumulation of a significant number of mutations that rival in number and variety the genetic lesions that lead initially to primary tumor formation. In fact, as evidence accumulates, it becomes increasingly plausible that metastatic dissemination does not depend on the acquisition of additional genetic lesions beyond those that are present in many primary tumors. (These discussions must focus on the mutant alleles that serve as ‘drivers’, i.e. those that were selected because they conferred advantageous biological phenotypes, rather than the ‘passenger’ mutations, which reflect the general increased mutability of tumor cell genomes and thereby constitute random genetic background noise.) ( 3 ) The evidence arguing against a necessary role of metastasis- specific mutations (acquired late) comes from at least three distinct sources. First, as has been documented on several occasions, one can, with some measure of success, determine the prognosis of primary tumors, especially their tendency to progress toward metastatic relapse, by examining the gene expression profile of these tumors. These gene expression profiles must reflect the differentiation program of the normal cell of origin as perturbed by the subsequently acquired somatic mutations (as well as promoter methylation events). For example, by using gene expression arrays to examine the transcription patterns of a large number of primary breast carcinomas, investigators have been able to predict, with some accuracy, which tumors are likely and which are unlikely to progress to metastatic relapse ( 4 , 5 ). This holds important implications for the mechanisms that govern metastasis, since they suggest that many cells, probably the great majority of neoplastic cells within a primary tumor, express a spectrum of genes that influence metastatic behavior. Conversely, this expression pattern cannot be that of a small minority subpopu
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Koopman Van Aarsen, L. A., Leone, D. R., Ho, S., Dolinski, B. M., McCoon, P. E., LePage, D. J., Kelly, R., Heaney, G., Rayhorn, P., Reid, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2307 · Cited by 146
Cited by
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
Parallel progression of primary tumours and metastases
Klein, C. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2627 · Cited by 1,133
Gjerdrum, C., Tiron, C., Høiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909333107 · Cited by 594
Metadata
- Authors
- Weinberg, R. A.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-15
- Volume
- 29
- Issue
- 6
- Pages
- 1092-1095
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2152387535
- Cited by
- 167
- References
- 3
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of malignant progression. https://app.cochat.ai/papers/10.1093/carcin/bgn104
- The paper
- Weinberg, R. A. (2008). Mechanisms of malignant progression. Carcinogenesis. https://doi.org/10.1093/carcin/bgn104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.